American Regent's anemia drug Injectafer wins FDA nod

The FDA approved American Regent's ferric carboxymaltose injection, or Injectafer, to treat iron deficiency anemia in adults. It is indicated for patients with nondialysis-dependent chronic kidney disease and in those who are intolerant or nonresponsive to oral iron. The drug is sold in Europe as Ferinject.

View Full Article in:

Pharmaceutical Business Review Online · PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Senior Scientist - Cell Engineering Group
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC